Phase I Study of Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
Status:
Not yet recruiting
Trial end date:
2030-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of using T lymphocyte chimeric antigen
receptor cells against the B7-H3 antigen (CAR.B7-H3T cells) in patients with glioblastoma.
CAR.B7-H3T cells treatment has not been tested in humans and is not an approved treatment by
the Food and Drug Administration for glioblastoma.